The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu(erb B-2) oncogene overexpression in cancer cells
Open accessAbstract
Fatty acid synthase (FAS) activity is a potential therapeutic target to treat cancer and obesity. Here, we have identified a molecular link between FAS and HER2(erb B-2) oncogene, a marker for poor prognosis that is overexpressed in 30% of breast and ovarian cancers. Pharmacological FAS inhibitors cerulenin and C75 were found to suppress p185HER2oncoprotein expression and tyrosine-kinase activity in breast and ovarian HER2 overexpressors. Similarly, p185HER2expression was dramatically down-regulated when FAS gene expression was silenced by using the highly sequence-specific mechanism of RNA interference (RNAi). Pharmacological and RNAi-mediated silencing of FAS specifically down-regulated HER2 mRNA and, concomitantly, caused a prominent up-regulation of PEA3, a transcriptional repressor of HER2. A cytoplasmic redistribution of p185HER2was associated with marked morphological changes of FAS RNAi-transfected cells, whereas chemical inhibitors of FAS promoted a striking nuclear accumulation of p185HER2. The simultaneous targeting of FAS and HER2 by chemical FAS inhibitors and the humanized antibody directed against p185HER2trastuzumab, respectively, was synergistically cytotoxic toward HER2 overexpressors. Similarly, concurrent RNAi-mediated silencing of FAS and HER2 genes synergistically stimulated apoptotic cell death in HER2 overexpressors. p185HER2was synergistically down-regulated after simultaneous inhibition of FAS and HER2 by either pharmacological inhibitors or small interfering RNA. These findings provide evidence of an active role of FAS in cancer evolution by specifically regulating oncogenic proteins closely related to malignant transformation, strongly suggesting that HER2 oncogene may act as the key molecular sensor of energy imbalance after the perturbation of tumor-associated FAS hyperactivity in cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80620-0 · Cited by 2,676
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Baselga, J. M., Norton, L., Albanell, J., Kim, Y. M., & Mendelsohn, J. M. (1998) · PubMed · Cited by 996
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934
Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology
Kuhajda, F. P. (2000) · Nutrition · doi:10.1016/s0899-9007(99)00266-x · Cited by 788
Fatty acid synthesis: a potential selective target for antineoplastic therapy
Kuhajda, F. P., Jenner, K., Wood, F. D., Hennigar, R. A., Jacobs, L. B., Dick, J. D., & Pasternack, G. R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6379 · Cited by 705
Synthesis and antitumor activity of an inhibitor of fatty acid synthase
Kuhajda, F. P., Pizer, E. S., Li, J. N., Mani, N. S., Frehywot, G. L., & Townsend, C. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3450 · Cited by 567
The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis
Omura, S. (1976) · Bacteriological Reviews · doi:10.1128/br.40.3.681-697.1976 · Cited by 493
Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma.
Milgraum, L. Z., Witters, L. A., Pasternack, G. R., & Kuhajda, F. P. (1997) · PubMed · Cited by 333
Alo, P. L., Visca, P., Marci, A., Mangoni, A., Botti, C., & Di Tondo, U. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960201)77:3<474::aid-cncr8>3.0.co;2-k · Cited by 313
Lane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., & Hynes, N. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3210-3223.2000 · Cited by 298
Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival
Gansler, T. S., Hardman, W., Hunt, D. A., Schaffel, S., & Hennigar, R. A. (1997) · Human Pathology · doi:10.1016/s0046-8177(97)90177-5 · Cited by 287
Sul, H. S., & Wang, D. (1998) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.18.1.331 · Cited by 280
Inhibition of fatty acid synthetases by the antibiotic cerulenin
Vance, D., Goldberg, I., Mitsuhashi, O., Bloch, K., Ōmura, S., & Nomura, S. (1972) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(72)90397-x · Cited by 278
Schrijver, E. D., Brusselmans, K., Heyns, W., Verhoeven, G., & Swinnen, J. V. (2003) · PubMed · Cited by 269
Mechanism of action of anti-HER2 monoclonal antibodies
Baselga, J., & Albanell, J. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s35 · Cited by 265
Swinnen, J. V., Ulrix, W., Heyns, W., & Verhoeven, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.12975 · Cited by 262
Selective activation of the fatty acid synthesis pathway in human prostate cancer
Swinnen, J. V., Vanderhoydonc, F., Elgamal, A. A., Eelen, M., Vercaeren, I., Joniau, S., Van Poppel, H., Baert, L., Goossens, K., Heyns, W., et al. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001015)88:2<176::aid-ijc5>3.0.co;2-3 · Cited by 245
Clinical trials of Herceptin® (trastuzumab)
Baselga, J. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00404-4 · Cited by 227
Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis.
Kumar‐Sinha, C., Ignatoski, K. W., Lippman, M. E., Ethier, S. P., & Chinnaiyan, A. M. (2003) · PubMed · Cited by 222
WEISS, L., HOFFMANN, G. E., SCHREIBER, R., ANDRES, H., FUCHS, E., KÖRBER, E., & KOLB, H. J. (1986) · Biological Chemistry Hoppe-Seyler · doi:10.1515/bchm3.1986.367.2.905 · Cited by 190
The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis
Xing, X., Wang, S.-C., Xia, W., Zou, Y., Shao, R., Kwong, K. Y., Yu, Z., Zhang, S., Miller, S., Huang, L., et al. (2000) · Nature Medicine · doi:10.1038/72294 · Cited by 164
Xie, Y., & Hung, M. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2368 · Cited by 134
Pizer, E. S., Wood, F. D., Pasternack, G. R., & Kuhajda, F. P. (1996) · PubMed · Cited by 132
Kuhajda, F. P., Piantadosi, S., & Pasternack, G. R. (1989) · New England Journal of Medicine · doi:10.1056/nejm198909073211003 · Cited by 130
Fatty Acid Synthase (Fas) Predictive Strength in Poorly Differentiated Early Breast Carcinomas
Alò, P., Visca, P., Trombetta, G., Mangoni, A., Lenti, L., Monaco, S., Botti, C., Serpieri, D. E., & Tondo, U. D. (1999) · Tumori Journal · doi:10.1177/030089169908500108 · Cited by 129
Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer
Tsai, M.-S., Shamon-Taylor, L. A., Mehmi, I., Tang, C. K., & Lupu, R. (2003) · Oncogene · doi:10.1038/sj.onc.1206130 · Cited by 121
Self-citationMenéndez, J. A., Mehmi, I., Atlas, E., Colomer, R., & Lupu, R. (2004) · International Journal of Oncology · doi:10.3892/ijo.24.3.591 · Cited by 113
Self-citationMenéndez, J. A., Lupu, R., & Colomer, R. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000018409.59448.60 · Cited by 82
Self-citationExpression of haptoglobin-related protein and its potential role as a tumor antigen.
Kuhajda, F. P., Katumuluwa, A. I., & Pasternack, G. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.4.1188 · Cited by 59
Nahta, R., Iglehart, J. D., Kempkes, B., & Schmidt, E. V. (2002) · PubMed · Cited by 48
Cited by
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941
Self-citationThe multifaceted roles of fatty acid synthesis in cancer
Röhrig, F., & Schulze, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.89 · Cited by 1,651
Reprogramming of fatty acid metabolism in cancer
Koundouros, N., & Poulogiannis, G. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0650-z · Cited by 1,614
Targeting cellular metabolism to improve cancer therapeutics
Zhao, Y., Butler, E. B., & Tan, M. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.60 · Cited by 989
Bian, X., Liu, R., Meng, Y., Xing, D., Xu, D., & Lu, Z. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201606 · Cited by 983
Metadata
- Authors
- Menendez, J. A., Vellon, L., Mehmi, I., Oza, B. P., Ropero, S., Colomer, R., & Lupu, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-07-02
- Volume
- 101
- Issue
- 29
- Pages
- 10715-10720
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2039731227
- Cited by
- 327
- References
- 35
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.